Nectin Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10M
- Investors
-
12
Nectin Therapeutics General Information
Description
Operator of a biotechnology company intended to treat solid and hematological malignancies. The company develops antibodies that overcome inhibitory pathways deployed by the tumors and help immune cells to effectively destroy cancer cells, enabling medical professionals to improve patient's lives with therapeutic options.
Contact Information
Website
www.nectintx.comCorporate Office
- Hi-Tech Campus Givat Ram
- POB 39135
- Jerusalem 91390
- Israel
Corporate Office
- Hi-Tech Campus Givat Ram
- POB 39135
- Jerusalem 91390
- Israel
Nectin Therapeutics Timeline
Nectin Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 06-May-2024 | $10M | Completed | Pre-Clinical Trials | ||
| 8. Accelerator/Incubator | 01-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 08-Nov-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 17-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 23-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series B) | 01-May-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 15-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Seed Round | 01-Jan-2017 | $1M | $1M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Nectin Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred A | ||||||||
| Preferred Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nectin Therapeutics Comparisons
Industry
Financing
Details
Nectin Therapeutics Competitors (6)
One of Nectin Therapeutics’s 6 competitors is Nkarta Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Nectin Therapeutics Patents
Nectin Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023346641-A1 | Humanized antibodies against nectin-4 and drug conjugates thereof | Pending | 20-Sep-2022 | ||
| EP-4590401-A1 | Humanized antibodies against nectin-4 and drug conjugates thereof | Pending | 20-Sep-2022 | ||
| US-20260014269-A1 | Humanized antibodies against nectin-4 and drug conjugates thereof | Pending | 20-Sep-2022 | ||
| WO-2024062476-A1 | Humanized antibodies against nectin-4 and drug conjugates thereof | Inactive | 20-Sep-2022 | ||
| AU-2023331612-A1 | Drug conjugates of humanized anti pvr antibodies | Pending | 04-Sep-2022 | A61K47/6851 |
Nectin Therapeutics Signals
Nectin Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Yissum | Accelerator/Incubator | |||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| Cancer Focus Fund | Venture Capital | Minority | ||
| Guangzhou Sino-Israel Bio-Industry Investment Fund | Venture Capital | Minority | ||
| IFB Group | Corporation | Minority |
Nectin Therapeutics FAQs
-
When was Nectin Therapeutics founded?
Nectin Therapeutics was founded in 2017.
-
Where is Nectin Therapeutics headquartered?
Nectin Therapeutics is headquartered in Jerusalem, Israel.
-
What is the size of Nectin Therapeutics?
Nectin Therapeutics has 11 total employees.
-
What industry is Nectin Therapeutics in?
Nectin Therapeutics’s primary industry is Biotechnology.
-
Is Nectin Therapeutics a private or public company?
Nectin Therapeutics is a Private company.
-
What is Nectin Therapeutics’s current revenue?
The current revenue for Nectin Therapeutics is .
-
How much funding has Nectin Therapeutics raised over time?
Nectin Therapeutics has raised $58M.
-
Who are Nectin Therapeutics’s investors?
Yissum, European Innovation Council, Cancer Focus Fund, Guangzhou Sino-Israel Bio-Industry Investment Fund, and IFB Group are 5 of 12 investors who have invested in Nectin Therapeutics.
-
Who are Nectin Therapeutics’s competitors?
Nkarta Therapeutics, Genetix Biotherapeutics, Inovio Pharmaceuticals, Kite Pharma, and Immunocore Holdings are some of the 6 competitors of Nectin Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process